portal hypertension

Summary

Summary: Abnormal increase of resistance to blood flow within the hepatic PORTAL SYSTEM, frequently seen in LIVER CIRRHOSIS and conditions with obstruction of the PORTAL VEIN.

Top Publications

  1. ncbi Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension
    Roberto de Franchis
    Gastroenterology and Gastrointestinal Endoscopy Service, Department of Internal Medicine, University of Milan, IRCCS Ospedale Maggiore Policlinico, Via Pace 9, 20122 Milan, Italy
    J Hepatol 43:167-76. 2005
  2. ncbi Esophageal capsule endoscopy for screening and surveillance of esophageal varices in patients with portal hypertension
    Roberto de Franchis
    Department of Medical Sciences, University of Milan, Istituto di Ricovero e Cura a Carattere Scientifico Fondazione Ospedale Maggiore Policlinico, Mangiagalli and Regina Elena, Milan, Italy
    Hepatology 47:1595-603. 2008
  3. pmc Feasibility of in vivo MR elastographic splenic stiffness measurements in the assessment of portal hypertension
    Jayant A Talwalkar
    Advanced Liver Diseases Study Group, Department of Gastroenterology and Hepatology, Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, Rochester, MN, USA
    AJR Am J Roentgenol 193:122-7. 2009
  4. ncbi Transient elastography accurately predicts presence of significant portal hypertension in patients with chronic liver disease
    C Bureau
    Service d Hepato gastro enterologie, Fédération Digestive, Purpan, CHU, Toulouse, France
    Aliment Pharmacol Ther 27:1261-8. 2008
  5. ncbi Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program
    Guadalupe Garcia-Tsao
    Department of Veterans Affairs Medical Center, West Haven, Connecticut, USA
    Am J Gastroenterol 104:1802-29. 2009
  6. ncbi Losartan prevents portal hypertension-induced, redox-mediated endothelial dysfunction in the mesenteric artery in rats
    Stéphanie Dal-Ros
    UMR CNRS 7213 Laboratoire de Biophotonique et de Pharmacologie, Faculte de Pharmacie, Universite de Strasbourg, Illkirch, France
    Gastroenterology 138:1574-84. 2010
  7. ncbi Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma
    Takeaki Ishizawa
    Hepato Biliary Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
    Gastroenterology 134:1908-16. 2008
  8. ncbi EUS for portal hypertension: a comprehensive and critical appraisal of clinical and experimental indications
    M el-Saadany
    Internal Medicine Department, Faculty of Medicine, Mansoura University, Egypt
    Endoscopy 40:690-6. 2008
  9. ncbi Esophageal capsule endoscopy vs. EGD for the evaluation of portal hypertension: a French prospective multicenter comparative study
    M G Lapalus
    Fédération des spécialités digestives, Hopital Edouard Herriot, Lyon, France
    Am J Gastroenterol 104:1112-8. 2009
  10. ncbi Etiology of portal hypertension may influence gastrointestinal transit
    R Sadik
    Division of Gastroenterology, Institute of Internal Medicine, Sahlgrenska University Hospital, University of Goteborg, Goteborg, Sweden
    Scand J Gastroenterol 38:1039-44. 2003

Detail Information

Publications350 found, 100 shown here

  1. ncbi Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension
    Roberto de Franchis
    Gastroenterology and Gastrointestinal Endoscopy Service, Department of Internal Medicine, University of Milan, IRCCS Ospedale Maggiore Policlinico, Via Pace 9, 20122 Milan, Italy
    J Hepatol 43:167-76. 2005
  2. ncbi Esophageal capsule endoscopy for screening and surveillance of esophageal varices in patients with portal hypertension
    Roberto de Franchis
    Department of Medical Sciences, University of Milan, Istituto di Ricovero e Cura a Carattere Scientifico Fondazione Ospedale Maggiore Policlinico, Mangiagalli and Regina Elena, Milan, Italy
    Hepatology 47:1595-603. 2008
    Bleeding from esophageal varices (EV) is a serious consequence of portal hypertension. Current guidelines recommend screening patients with cirrhosis with esophagogastroduodenoscopy (EGD) to detect varices...
  3. pmc Feasibility of in vivo MR elastographic splenic stiffness measurements in the assessment of portal hypertension
    Jayant A Talwalkar
    Advanced Liver Diseases Study Group, Department of Gastroenterology and Hepatology, Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, Rochester, MN, USA
    AJR Am J Roentgenol 193:122-7. 2009
    Liver stiffness is associated with portal hypertension in patients with chronic liver disease. However, the relation between spleen stiffness and clinically significant portal hypertension remains unknown...
  4. ncbi Transient elastography accurately predicts presence of significant portal hypertension in patients with chronic liver disease
    C Bureau
    Service d Hepato gastro enterologie, Fédération Digestive, Purpan, CHU, Toulouse, France
    Aliment Pharmacol Ther 27:1261-8. 2008
    ..Hepatic venous pressure gradient (HVPG) is a prognostic marker in patients with cirrhosis. Transient elastography measures liver stiffness (LS)...
  5. ncbi Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program
    Guadalupe Garcia-Tsao
    Department of Veterans Affairs Medical Center, West Haven, Connecticut, USA
    Am J Gastroenterol 104:1802-29. 2009
    ..A rational management of cirrhosis will result in improvements in quality of life, treatment adherence, and, ultimately, in outcomes...
  6. ncbi Losartan prevents portal hypertension-induced, redox-mediated endothelial dysfunction in the mesenteric artery in rats
    Stéphanie Dal-Ros
    UMR CNRS 7213 Laboratoire de Biophotonique et de Pharmacologie, Faculte de Pharmacie, Universite de Strasbourg, Illkirch, France
    Gastroenterology 138:1574-84. 2010
    Advanced stages of portal hypertension are characterized by generalized vasodilatation and a hyperdynamic syndrome that leads to complications such as hepatopulmonary syndrome...
  7. ncbi Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma
    Takeaki Ishizawa
    Hepato Biliary Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
    Gastroenterology 134:1908-16. 2008
    The surgical indications for multiple hepatocellular carcinomas (HCCs) and for HCC with portal hypertension (PHT) remain controversial.
  8. ncbi EUS for portal hypertension: a comprehensive and critical appraisal of clinical and experimental indications
    M el-Saadany
    Internal Medicine Department, Faculty of Medicine, Mansoura University, Egypt
    Endoscopy 40:690-6. 2008
    ..EUS) has significantly improved our understanding of the complex vascular structural changes that occur in portal hypertension and their clinical and prognostic significance...
  9. ncbi Esophageal capsule endoscopy vs. EGD for the evaluation of portal hypertension: a French prospective multicenter comparative study
    M G Lapalus
    Fédération des spécialités digestives, Hopital Edouard Herriot, Lyon, France
    Am J Gastroenterol 104:1112-8. 2009
    ..Esophagogastroduodenoscopy (EGD) is the standard method for the diagnosis of esophago-gastric varices. The aim of this prospective multicenter study was to evaluate the PillCam esophageal capsule endoscopy (ECE) for this indication...
  10. ncbi Etiology of portal hypertension may influence gastrointestinal transit
    R Sadik
    Division of Gastroenterology, Institute of Internal Medicine, Sahlgrenska University Hospital, University of Goteborg, Goteborg, Sweden
    Scand J Gastroenterol 38:1039-44. 2003
    Gastrointestinal transit studies have shown contradictory results in patients with portal hypertension. We have studied gastric emptying. small-bowel transit and colonic transit in patients with portal hypertension...
  11. ncbi The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule
    Yasuko Iwakiri
    Hepatic Hemodynamic Laboratory, VA Connecticut Healthcare System, West Haven, CT 06516, USA
    Hepatology 43:S121-31. 2006
    ..first, clinical observation in patients; second, experimental models used to study the hyperdynamic circulatory syndrome; and third, the vasodilator molecules that play roles in vascular abnormalities observed in portal hypertension.
  12. ncbi Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation
    José A Carrión
    Liver Unit, Institut de Malalties Digestives, Centre de Diagnòstic per l Imatge, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Barcelona, Spain
    Liver Transpl 12:1791-8. 2006
    ..84; P < 0.001) and the AUC for diagnosis of portal hypertension (HVPG >or=6 mm Hg) was 0.93...
  13. ncbi Noninvasive assessment of liver fibrosis and portal hypertension with transient elastography
    Don C Rockey
    Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Gastroenterology 134:8-14. 2008
    ..believed to be a critical factor leading to hepatic dysfunction and may be important in the pathogenesis of portal hypertension. Thus, accurate assessment of the degree of fibrosis is important clinically...
  14. ncbi Natural history of portal hypertension in patients with cirrhosis
    R de Franchis
    Department of Internal Medicine, University of Milan, Italy
    Clin Liver Dis 5:645-63. 2001
    All patients with cirrhosis will eventually develop portal hypertension and esophagogastric varices...
  15. ncbi Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicentre study
    Christophe Bureau
    Federation Digestive Purpan, Service Hepato Gastro Enterologie CHU Toulouse, Toulouse, France
    Liver Int 27:742-7. 2007
    ..the use of transjugular intrahepatic portosystemic shunts (TIPS) in the treatment of complications of portal hypertension. The use of covered stents could improve shunt patency; however, long-term effect and safety remain unknown...
  16. ncbi Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis
    Francesco Vizzutti
    Dipartimento di Medicina Interna, Center for Research, Higher Education and Transfer DENOThe, Firenze, Italy
    Hepatology 45:1290-7. 2007
    ..In this study, we evaluated the ability of LSM to predict severe portal hypertension compared with that of HVPG in 61 consecutive patients with HCV-related chronic liver disease...
  17. ncbi Role of spleen enlargement in cirrhosis with portal hypertension
    M Bolognesi
    Department of Clinical and Experimental Medicine, University of Padua, Italy
    Dig Liver Dis 34:144-50. 2002
    The possible relationships between splenomegaly and portal hypertension have been analysed in patients with cirrhosis...
  18. ncbi Long-term results of balloon-occluded retrograde transvenous obliteration for the treatment of gastric varices and hepatic encephalopathy
    T Fukuda
    Department of Radiology, Kobe University School of Medicine, Japan
    J Vasc Interv Radiol 12:327-36. 2001
    ..To evaluate the long-term results of balloon-occluded retrograde transvenous obliteration (B-RTO) for the treatment of gastric varices (GV) and hepatic encephalopathy...
  19. ncbi Benign nodular hepatocellular lesions caused by abnormal hepatic circulation: etiological analysis and introduction of a new concept
    F Kondo
    Department of Molecular Pathology, Chiba University School of Medicine, Chiba, Japan
    J Gastroenterol Hepatol 16:1319-28. 2001
    ..hyperplasia (FNH), nodular regenerative hyperplasia (NRH), nodular lesions associated with idiopathic portal hypertension (IPH), non-cirrhotic large regenerative nodules (LRN), hepatocellular adenoma (HA)-like hyperplastic ..
  20. ncbi The impact of cirrhosis and portal hypertension on mortality following colorectal surgery: a nationwide, population-based study
    Geoffrey C Nguyen
    Mount Sinai Hospital Division of Gastroenterology, University of Toronto, Toronto, Ontario, Canada
    Dis Colon Rectum 52:1367-74. 2009
    Population-based data on outcomes associated with colorectal procedures in cirrhotic patients are sparse. We sought to assess the impact of liver cirrhosis and portal hypertension on mortality following colorectal surgery.
  21. ncbi Austrian consensus on the definition and treatment of portal hypertension and its complications
    M Peck-Radosavljevic
    Medizinische Universität Wien, Klinik Innere Medizin IV, Abteilung Gastroenterologie und Hepatologie
    Endoscopy 37:667-73. 2005
  22. ncbi [Non-invasive diagnosis of portal hypertension in cirrhosis. Application to the primary prevention of varices]
    Nina Dib
    Laboratoire HIFIH, UPRES EA 3859, IFR 132, Université et Service d Hépato Gastroentérologie, CHU, Angers
    Gastroenterol Clin Biol 29:975-87. 2005
    One of the major complications of cirrhosis is the occurrence of portal hypertension and esophageal varices...
  23. ncbi Partial splenic embolization in the treatment of patients with portal hypertension: a review of the english language literature
    Kristen Gledhill Koconis
    Department of Radiology, Penn State Heart and Vascular Institute, Pennsylvania State Milton S Hershey Medical Center, 500 University Drive, Hershey, PA 17033, USA
    J Vasc Interv Radiol 18:463-81. 2007
    This article reviews the existing literature on the use of partial splenic embolization in patients with portal hypertension. All articles published in the English language on splenic embolization or partial splenic embolization as a ..
  24. ncbi [The role of activated hepatic stellate cells in liver fibrosis, portal hypertension and cancer angiogenesis]
    June Sung Lee
    Department of Internal Medicine, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea
    Korean J Hepatol 13:309-19. 2007
    ..In the liver, these processes are particularly important in the development of cirrhosis, portal hypertension and cancer...
  25. ncbi Hepatic flow parameters measured with MR imaging and Doppler US: correlations with degree of cirrhosis and portal hypertension
    Laurence Annet
    Department of Radiology, Universite Catholique de Louvain, St Luc University Hospital, Avenue Hippocrate 10, B 1200 Brussels, Belgium
    Radiology 229:409-14. 2003
    To determine the correlations between hemodynamic parameters of hepatic flow measured with magnetic resonance (MR) imaging and Doppler ultrasonography (US) and the severity of cirrhosis and portal hypertension.
  26. ncbi A role for asymmetric dimethylarginine in the pathophysiology of portal hypertension in rats with biliary cirrhosis
    Wim Laleman
    Laboratories of Hepatology, University Hospital Gasthuisberg, Leuven, Belgium
    Hepatology 42:1382-90. 2005
    Reduced intrahepatic endothelial nitric oxide synthase (eNOS) activity contributes to the pathogenesis of portal hypertension (PHT) associated with cirrhosis...
  27. ncbi Transjugular intrahepatic portosystemic shunt for palliative treatment of portal hypertension secondary to portal vein tumor thrombosis
    Zai bo Jiang
    3rd Affiliated Hospital of SUN YAT SEN University, Guangzhou 510630, Guangdong Province, China
    World J Gastroenterol 10:1881-4. 2004
    To evaluate the palliative therapeutic effects of transjugular intrahepatic portosystemic shunt (TIPS) in portal vein tumor thrombosis (PVTT) complicated by portal hypertension.
  28. ncbi Relevance of the mTOR signaling pathway in the pathophysiology of splenomegaly in rats with chronic portal hypertension
    Marc Mejias
    Liver Unit, Institute of Biomedical Research IDIBAPS, CIBERehd, Hospital Clinic, University of Barcelona, Villarroel 170, Barcelona, Spain
    J Hepatol 52:529-39. 2010
    Splenomegaly is a frequent hallmark of portal hypertension that, in some cases, can be very prominent and cause symptoms like abdominal pain, splenic infarction, and cytopenia...
  29. ncbi The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis
    C Merkel
    Department of Clinical and Experimental Medicine, University of Padua, Padua, Italy
    Hepatology 32:930-4. 2000
    ..In conclusion, the assessment of hemodynamic response to drugs in terms of HVPG is the best predictor of efficacy of prophylaxis of variceal bleeding in patients treated with beta-blockers or beta-blockers plus nitrates...
  30. pmc Pre- and postoperative systemic hemodynamic evaluation in patients subjected to esophagogastric devascularization plus splenectomy and distal splenorenal shunt: a comparative study in schistomomal portal hypertension
    Roberto de Cleva
    Gastroenterology Department, University of Sao Paulo Medical School, Rua Cel Artur Godoy 125, Apto 152 Vila Mariana, Sao Paulo, SP 04018 050, Brazil
    World J Gastroenterol 13:5471-5. 2007
    To investigate the systemic hemodynamic effects of two surgical procedures largely employed for treatment of schistosomal portal hypertension.
  31. ncbi Superoxide dismutase gene transfer reduces portal pressure in CCl4 cirrhotic rats with portal hypertension
    B Laviña
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, Barcelona, Spain
    Gut 58:118-25. 2009
    ..NO scavenging by superoxide (O(2)(-)) further contributes to a reduction of NO bioavailability in cirrhotic livers...
  32. ncbi Esophageal capsule endoscopy versus esophagogastroduodenoscopy for evaluating portal hypertension: a prospective comparative study of performance and tolerance
    M G Lapalus
    Dept of Digestive Diseases, Edouard Herriot Hospital Lyon, France
    Endoscopy 38:36-41. 2006
    ..the most effective method for examining the upper gastrointestinal tract, and particularly for evaluating portal hypertension in cirrhotic patients, especially for screening purposes...
  33. ncbi Portal hypertension due to a splenic arteriovenous fistula: a case report
    Mauricio Orrego
    Division of Transplantation Medicine, Mayo Clinic, Scottsdale, Arizona, USA
    Dig Dis Sci 51:1113-6. 2006
  34. ncbi EUS analysis of collateral veins inside and outside the esophageal wall in portal hypertension
    A Irisawa
    Department of Internal Medicine II, Fukushima Medical University, School of Medicine, Fukushima City, Japan
    Gastrointest Endosc 50:374-80. 1999
    The relation between esophageal varices and venous collaterals outside the esophageal wall in patients with portal hypertension remains unclear. We investigated this relationship with endoscopy and endoscopic ultrasound (US).
  35. ncbi Endoscopic treatments for portal hypertension
    R de Franchis
    Dipartimento di Medicina Interna, University of Milan, Italy
    Semin Liver Dis 19:439-55. 1999
    ..As of today, endoscopic treatments are not recommended for the primary prophylaxis of variceal bleeding...
  36. ncbi Modifications produced by indomethacin and L-NAME in the effect of ultralow-dose aspirin on platelet activity in portal hypertension
    Francisco X Eizayaga
    Facultad de Medicina, Universidad Maimónides, Buenos Aires, Argentina
    Pathophysiol Haemost Thromb 35:357-63. 2006
    ..we demonstrated the effect of ultralow-dose aspirin (ULDA) on platelet activity and bleeding in rats with portal hypertension (PHT) produced by portal vein ligation (PVL)...
  37. ncbi Cure of gastric antral vascular ectasia by liver transplantation despite persistent portal hypertension: a clue for pathogenesis
    Catherine Vincent
    Liver Unit, Hopital Saint Luc, Hôpital du Saint Sacrement and Université Laval, Quebec, Canada
    Liver Transpl 8:717-20. 2002
    ..It has been suggested that these gastric lesions might be related to portal hypertension, hepatic insufficiency, or both parameters...
  38. ncbi Balloon-occluded retrograde transvenous obliteration improves liver function in patients with cirrhosis and portal hypertension
    Yasunao Miyamoto
    Department of Medicine II, Division of Gastroenterology and Endoscopy, Kurume University School of Medicine, Kurume, Japan
    J Gastroenterol Hepatol 18:934-42. 2003
    ..However, the effects of B-RTO on liver function remain unknown...
  39. ncbi Favorable clinical outcome using a covered stent following transjugular intrahepatic portosystemic shunt in patients with portal hypertension
    Xingjiang Wu
    Research Institute of General Surgery, Jinling Hospital, Nanjing University School of Medicine, 305 East Zhongshan Road, Nanjing, 210002, Jiangsu, China
    J Hepatobiliary Pancreat Sci 17:701-8. 2010
    ..To compare retrospectively the clinical outcomes in patients treated with transjugular intrahepatic portosystemic shunt (TIPS) using the novel polytetrafluoroethylene-covered stents (Fluency) and bare stents...
  40. ncbi Portal hypertension: from bedside to bench
    Roberto J Groszmann
    Veterans Administration Medical Center, West Haven, CT 06516, USA
    J Clin Gastroenterol 39:S125-30. 2005
    The initial factor leading to portal hypertension is an increase in hepatic resistance...
  41. ncbi Endoscopic ultrasonography in the diagnosis and management of portal hypertension. Where are we next?
    S N Sgouros
    Department of Gastroenterology, Athens Naval and Veterans Hospital, Nafpaktias 5, Agia Paraskevi, 15341 Athens, Greece
    Dig Liver Dis 38:289-95. 2006
    ..emerged as an accurate, non-invasive and reproducible alternative means of providing data for patients with portal hypertension. It is well established that endoscopic ultrasonography is more sensitive than endoscopy in the diagnosis ..
  42. ncbi Enteroscopic cyanoacrylate sclerotherapy of jejunal and gallbladder varices in a patient with portal hypertension
    S Getzlaff
    Dept. of Gastroenterology, City Hospital, Ludwigshafen am Rhein (University of Mainz Medical School, Germany
    Endoscopy 33:462-4. 2001
    Bleeding from varices outside the gastroesophageal region is a rare, but regularly reported complication of portal hypertension. The treatment differs from the management of esophageal and gastric varices...
  43. doi Portal hypertension and its complications
    Arun J Sanyal
    Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University Medical Center, Richmond, Virginia, USA
    Gastroenterology 134:1715-28. 2008
  44. ncbi Effect of portal hypertension in the small bowel: an endoscopic approach
    Pedro Figueiredo
    Department of Gastroenterology, Hospitais da Universidade de Coimbra, Coimbra, Portugal
    Dig Dis Sci 53:2144-50. 2008
    The effects of portal hypertension in the small bowel are largely unknown. The aim of the study was to prospectively assess portal hypertension manifestations in the small bowel.
  45. ncbi Adenosine reverses a preestablished CCl4-induced micronodular cirrhosis through enhancing collagenolytic activity and stimulating hepatocyte cell proliferation in rats
    R Hernandez-Munoz
    Departamento de Biologia Celular, Instituto de Fisiologia Celular, Universidad Nacional Autonoma de Mexico
    Hepatology 34:677-87. 2001
    ..liver fibronectin and collagen types I and III content, enhanced expression of alpha-1 (I) collagen mRNA, portal hypertension, and liver dysfunction...
  46. ncbi Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial
    Juan G Abraldes
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Spain
    Gastroenterology 136:1651-8. 2009
    ..and hepatic endothelial dysfunction in patients with cirrhosis, so it could be an effective therapy for portal hypertension. This randomized controlled trial evaluated the effects of continuous simvastatin administration on the ..
  47. ncbi Racial disparities in the management of hospitalized patients with cirrhosis and complications of portal hypertension: a national study
    Geoffrey C Nguyen
    Division of Gastroenterology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Hepatology 45:1282-9. 2007
    Having complications of portal hypertension is a harbinger of decompensated cirrhosis and warrants consideration for liver transplantation (LT). Racial disparities in LT have been reported...
  48. ncbi Short-term complications of retrograde transvenous obliteration of gastric varices in patients with portal hypertension: effects of obliteration of major portosystemic shunts
    R Shimoda
    Gastroenterology Division, Maebashi Red Cross Hospital, Maebashi, Japan
    Abdom Imaging 30:306-13. 2005
    ..Thus, B-RTO is a safe and effective management of fundic varices. However, short-term hemodynamic change after B-RTO may cause gastric mucosal damage. Pulmonary infarction and pleural effusion are potential complications...
  49. ncbi Using capsule endoscopy to identify GI tract lesions in cirrhotic patients with portal hypertension and chronic anemia
    Karen R Canlas
    Division of Gastroenterology and Hepatology, Duke University Medical Center, Durham, NC 27705, USA
    J Clin Gastroenterol 42:844-8. 2008
    We aimed to evaluate the ability of capsule endoscopy (CE) to detect small intestine (SI) lesions, especially SI varices, in patients with intrahepatic cirrhosis, portal hypertension (PHTN), and chronic anemia.
  50. ncbi Recent variceal bleeding: Doppler US hepatic vein waveform in assessment of severity of portal hypertension and vasoactive drug response
    Soon Koo Baik
    Department of Internal Medicine, Yonsei University Wonju College of Medicine, 162 Ilsan dong, Wonju 220 701, South Korea
    Radiology 240:574-80. 2006
    ..To prospectively evaluate both the correlation between abnormal Doppler ultrasonography (US) hepatic vein waveforms and the hepatic venous pressure gradient (HVPG) and the response to drug treatment in patients with cirrhosis...
  51. ncbi Comparison of Doppler ultrasonography and the hepatic venous pressure gradient in assessing portal hypertension in liver cirrhosis
    Yeun Jong Choi
    Departments of Internal Medicine, Wonju College of Medicine, Wonju, Korea
    J Gastroenterol Hepatol 18:424-9. 2003
    ..whether Doppler ultrasonography can represent the hepatic venous pressure gradient (HVPG) as an assessment of the severity of portal hypertension and the response to terlipressin, which reduces the portal pressure in liver cirrhosis.
  52. ncbi Amiloride reduces portal hypertension in rat liver cirrhosis
    Christian J Steib
    Department of Medicine II Gastroenterology and Hepatology, Liver Center Munich, University of Munich e Grosshadern, Munich 81377, Germany
    Gut 59:827-36. 2010
    This study aimed to investigate the effect of amiloride on portal hypertension. Amiloride is known to inhibit Na(+)/H(+) exchangers on activated hepatic stellate cells.
  53. ncbi Diagnosis and monitoring of portal hypertension
    R de Franchis
    Department of Medical Sciences, University of Milan, Italy
    Dig Liver Dis 40:312-7. 2008
    ....
  54. ncbi Clinical and laboratory predictors of esophageal varices in children and adolescents with portal hypertension syndrome
    Eleonora Druve Tavares Fagundes
    Department of Pediatrics, Hospital das Clinicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
    J Pediatr Gastroenterol Nutr 46:178-83. 2008
    To determine the clinical and laboratory parameters that may predict the presence of esophageal varices in children and adolescents with portal hypertension.
  55. ncbi The management of portal hypertension: rational basis, available treatments and future options
    Jaime Bosch
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, University of Barcelona, Hospital Clinic, C Villarroel 170, 08036 Barcelona, Spain
    J Hepatol 48:S68-92. 2008
    ..This article reviews the rationale for the management of patients with cirrhosis and portal hypertension, the current recommendations for the prevention and treatment of variceal bleeding, and outlines the ..
  56. ncbi [Pathophysiology of portal hypertension, what's new?]
    Moon Young Kim
    Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea
    Korean J Gastroenterol 56:129-34. 2010
    b>Portal hypertension (PHT) is associated with changes in the intrahepatic, systemic and portosystemic collateral circulations...
  57. ncbi Apelin signaling modulates splanchnic angiogenesis and portosystemic collateral vessel formation in rats with portal hypertension
    Carolina Tiani
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Hospital Clinic, CIBERehd, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain
    J Hepatol 50:296-305. 2009
    Angiogenesis is a pathological hallmark of portal hypertension. Although VEGF is considered to be the most important proangiogenic factor in neoangiogenesis, this process requires the coordinated action of a variety of factors...
  58. ncbi Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension
    Steingerdur Anna Gunnarsdottir
    Department of Internal Medicine, Section of Gastroenterology and Hepatology, Sahlgrenska University Hospital, Goteborg, Sweden
    Am J Gastroenterol 98:1362-70. 2003
    ..Our aim was to explore the relationship between motility abnormalities, portal hypertension, and SIBO.
  59. ncbi Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding
    Alberto Monescillo
    Digestive Disease Department, Hospital Universitario Insular de Gran Canaria, Canary Islands, Spain
    Hepatology 40:793-801. 2004
    ....
  60. ncbi The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough
    Reiner Wiest
    Hepatic Hemodynamic Laboratory, Veterans Administration Medical Center, West Haven, Connecticut 06516, USA
    Hepatology 35:478-91. 2002
  61. doi Portal hypertension and variceal bleeding--unresolved issues. Summary of an American Association for the study of liver diseases and European Association for the study of the liver single-topic conference
    Guadalupe Garcia-Tsao
    Section of Digestive Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA
    Hepatology 47:1764-72. 2008
  62. ncbi The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension
    Thomas D Boyer
    Liver Research Institute, University of Arizona School of Medicine, Tucson, AZ 85750, USA
    Hepatology 41:386-400. 2005
  63. ncbi Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension
    Jaume Bosch
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic IDIBAPS and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Spain
    J Hepatol 53:558-67. 2010
    b>Portal hypertension is the main cause of complications in patients with chronic liver disease...
  64. ncbi Liver stiffness measurement as a predictive tool of clinically significant portal hypertension in patients with compensated hepatitis C virus or alcohol-related cirrhosis
    M Lemoine
    Service d Hepatologie, Hopital Jean Verdier, AP HP, Bondy, France
    Aliment Pharmacol Ther 28:1102-10. 2008
    Hepatic venous pressure gradient (HVPG) is the gold standard for assessing the presence and the severity of portal hypertension (PHT). Liver stiffness measurement (LSM) is a non-invasive method for liver fibrosis assessment.
  65. ncbi Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis
    Rafael Bañares
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital General Universitario Gregorio Maranon, Universidad Complutense, Madrid, Spain
    Hepatology 36:1367-73. 2002
    ..However, its clinical applicability may be limited by its systemic hypotensive effects. Further trials are needed to confirm the therapeutic potential of carvedilol...
  66. ncbi Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis
    Juan G Abraldes
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut de Malalties Digestives, Hospital Clinic, Institut de Investigacions Biomèdiques August Pi i Sunyer IDIBAPS, Universitat de Barcelona, Barcelona, Spain
    Hepatology 37:902-8. 2003
    In cirrhotic patients under pharmacologic treatment for portal hypertension, a reduction in hepatic venous pressure gradient (HVPG) of >or=20% of baseline or to <or=12 mm Hg markedly reduces the risk of variceal rebleeding...
  67. ncbi ET-1 and TNF-alpha in HPS: analysis in prehepatic portal hypertension and biliary and nonbiliary cirrhosis in rats
    Bao Luo
    Department of Internal Medicine, University of Alabama at Birmingham, Birmingham, AL 35294 0005, USA
    Am J Physiol Gastrointest Liver Physiol 286:G294-303. 2004
    ..We evaluated for HPS in rat prehepatic portal hypertension [partial portal vein ligation (PVL)], biliary (CBDL) and nonbiliary [thioacetamide treatment (TAA)] ..
  68. ncbi Mesenterico left portal bypass for variceal bleeding owing to extrahepatic portal hypertension caused by portal vein thrombosis
    Oguz Ates
    Department of Pediatric Surgery and Radiology, Dokuz Eylul University, Medical School and Behçet Uz Children s Hospital, Clinic of Pediatric Surgery, 35340, Balcova, Izmir, Turkey
    J Pediatr Surg 41:1259-63. 2006
    Portosystemic shunt operations are indicated in patients with extrahepatic portal hypertension owing to portal vein thrombosis (EPH-PVT) suffering from recurrent variceal bleeding despite endoscopic sclerotherapy...
  69. ncbi Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury
    Julian H Slade
    Department of Pharmacy, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Clin Colorectal Cancer 8:225-30. 2009
    ..chemotherapy in 6 patients with stage III or IV CRC who developed evidence of noncirrhotic portal hypertension. These patients developed complications of portal hypertension including esophageal or hemorrhoidal varices ..
  70. pmc Endothelial to mesenchymal transition via transforming growth factor-beta1/Smad activation is associated with portal venous stenosis in idiopathic portal hypertension
    Azusa Kitao
    MD, PhD, Department of Human Pathology, Kanazawa University Graduate School of Medicine, 13 1 Takara machi, Kanazawa 920 8640, Japan
    Am J Pathol 175:616-26. 2009
    Idiopathic portal hypertension (IPH) represents noncirrhotic portal hypertension of unknown etiology, mainly due to stenosis of peripheral portal veins...
  71. ncbi Is portal hypertension a contraindication to hepatic resection?
    Alessandro Cucchetti
    Liver and Multiorgan Transplant Unit, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Ann Surg 250:922-8. 2009
    ..remarkably in recent years with improved surgical techniques and perioperative care; however, the role of portal hypertension is still uncertain...
  72. pmc Portal hypertension due to portal venous thrombosis: etiology, clinical outcomes
    Ozgur Harmanci
    Hacettepe University Faculty of Medicine, Department of Gastroenterology, Sihhiye, Ankara, Turkey
    World J Gastroenterol 13:2535-40. 2007
    ..these complications of portal vein thrombosis are not different from their counterpart which is cirrhotic portal hypertension, but the prognosis is unquestionably better in former cases...
  73. ncbi Portal hypertension and variceal hemorrhage
    Nagib Toubia
    Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University School of Medicine, MCV, Box 980341, Richmond, VA 23298 0341, USA
    Med Clin North Am 92:551-74, viii. 2008
    b>Portal hypertension, a major hallmark of cirrhosis, is defined as a portal pressure gradient exceeding 5 mm Hg. In portal hypertension, porto-systemic collaterals decompress the portal circulation and give rise to varices...
  74. ncbi Review article: the modern management of portal hypertension--primary and secondary prophylaxis of variceal bleeding in cirrhotic patients
    J C Garcia-Pagan
    Liver Unit, Hepatic Hemodynamic Laboratory, Hospital Clinic, IDIBAPS and Ciberehd, Barcelona, Spain
    Aliment Pharmacol Ther 28:178-86. 2008
    ..Variceal bleeding is a life-threatening complication of liver cirrhosis with a high probability of recurrence. Treatment to prevent first bleeding or rebleeding is mandatory...
  75. ncbi Antifibrotic activity of rofecoxib in vivo is associated with reduced portal hypertension in rats with carbon tetrachloride-induced liver injury
    Chuan Tao Tu
    Division of Digestive Diseases, Zhong Shan Hospital, Department of Internal Medicine, Shanghai Medical Collage, Fu Dan University, Shanghai, China
    J Gastroenterol Hepatol 22:877-84. 2007
    ..The aim of this study was to investigate the effects of selective inhibition of COX-2 on the development of liver cirrhosis and portal hypertension in rats.
  76. ncbi Mechanisms of extrahepatic vasodilation in portal hypertension
    M Hennenberg
    Department of Internal Medicine I, University of Bonn, Sigmund Freud Str 25, D 53105 Bonn, Germany
    Gut 57:1300-14. 2008
    ..extrahepatic vasodilation leads to hyperdynamic circulatory dysfunction which essentially contributes to portal hypertension. Since portal hypertension is a major factor in the development of complications in cirrhosis, the ..
  77. ncbi The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension
    Luis Colombato
    Hepatic Hemodynamic Section, Liver Unit, Gastroenterology Department, Buenos Aires British Hospital, Buenos Aires School of Medicine, Buenos Aires University, Buenos Aires, Argentina
    J Clin Gastroenterol 41:S344-51. 2007
    ..Pre-TIPS evaluation taking into account predictors of outcome is mandatory. The improved results achieved with covered-stents might expand the currently accepted recommendations for TIPS use...
  78. ncbi Noninvasive prediction of clinically significant portal hypertension and esophageal varices in patients with compensated liver cirrhosis
    Annalisa Berzigotti
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut d Investigacions Biomèdiques August Pi i Sunyer IDIBAPS and Centro de Investigación Biomèdica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, University of Barcelona, Barcelona, Spain
    Am J Gastroenterol 103:1159-67. 2008
    We aimed to develop a model based on noninvasive variables for the prediction of clinically significant portal hypertension (CSPH) and of esophageal varices (EV) in patients with compensated liver disease.
  79. ncbi Intraperitoneal LPS amplifies portal hypertension in rat liver fibrosis
    Christian J Steib
    Department of Medicine II Gastroenterology and Hepatology, Liver Center Munich, University of Munich Grosshadern, Munich, Germany
    Lab Invest 90:1024-32. 2010
    ..In this study, we hypothesized that pretreatment with intraperitoneal LPS may escalate portal hypertension. In fibrotic livers (4 weeks after bile duct ligation, BDL), the activation of Kupffer cells (KCs) by ..
  80. ncbi Endothelial dysfunction in cirrhosis and portal hypertension
    P A Cahill
    School of Biotechnology, Dublin City University, Glasnevin Dublin 9, Ireland
    Pharmacol Ther 89:273-93. 2001
    b>Portal hypertension (PHT) is a common clinical syndrome associated with chronic liver diseases; it is characterized by a pathological increase in portal pressure...
  81. ncbi [Surgical treatment of portal hypertension]
    M Wolff
    Klinik und Poliklinik für Allgemein, Viszeral, Thorax und Gefasschirurgie, Rheinische Friedrich Wilhelms Universitat, Bonn
    Zentralbl Chir 130:238-45. 2005
    ..For patients with noncirrhotic portal hypertension, in particular with extrahepatic portal vein thrombosis, portosystemic shunt surgery represents the only ..
  82. ncbi Isolated right-sided varicocele as a salvage pathway for portal hypertension
    G M Pinggera
    Department of Urology, Medical University Innsbruck, Austria
    Int J Clin Pract 59:740-2. 2005
    ..In such cases, standard approaches to infertility treatment are fruitless...
  83. ncbi Effects of combined splenorenal shunt devascularization and devascularization only on hemodynamics of the portal venous system in patients with portal hypertension
    Hui Cao
    Department of General Surgery, Renji Hospital, Shanghai 200127, China
    Hepatobiliary Pancreat Dis Int 4:385-8. 2005
    ..This study aimed to evaluate effects on hemodynamics of the portal venous system after conventional splenorenal shunt combined with pericardial devascularization and pericardial devascularization only...
  84. ncbi Surgery is inadvisable: massive varicocele due to portal hypertension
    Heinrich Schulte-Baukloh
    Department of Urology, St Hedwig Hospital, Teaching Hospital of University Hospital Charité, Berlin, Germany
    Int J Urol 12:852-4. 2005
    ..As a very rare finding we describe a patient who presented with an exorbitant left sided varicocele due to portal hypertension. We were well advised to avoid surgery.
  85. ncbi Role of nitric oxide synthase and cyclooxygenase in hyperdynamic splanchnic circulation of portal hypertension
    Jia Xu
    Department of General Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China
    Hepatobiliary Pancreat Dis Int 7:503-8. 2008
    ..and prostacyclin (PGI2) are both powerful vasoactive substances correlated with the hyperhemodynamics of portal hypertension (PHT), a common syndrome characterized by a pathological increase in portal venous pressure...
  86. ncbi Left-sided portal hypertension caused by serous cystadenoma of the pancreas: report of a case
    Koji Ito
    Department of Hepato Biliary Pancreatic Surgery, Tokyo Medical and Dental University, Graduate School of Medicine, 1 5 45 Yushima, Bunkyo ku, Tokyo, 113 8519, Japan
    Surg Today 38:184-7. 2008
    We report a case of serous cystadenoma of pancreas causing left-sided portal hypertension and gastric varices. A 68-year-old man was admitted for treatment of a pancreatic body tumor...
  87. ncbi Restriction of drinking water abrogates splanchnic vasodilation and portal hypertension in portal vein-ligated rats
    Akos Heinemann
    Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria
    Pharmacology 83:26-32. 2009
    b>Portal hypertension is associated with splanchnic vasodilation which is claimed responsible for the maintenance of chronically elevated portal pressure...
  88. ncbi Extrahepatic portal hypertension treated by anastomosing inferior mesenteric vein to left portal vein at Rex recessus
    Oguz Ates
    Department of Pediatric Surgery, Dokuz Eylul University, Medical School, Izmir, Turkey
    J Pediatr Surg 38:E10-1. 2003
    ..significant hypersplenism, portosystemic shunt procedures should be performed in cases of extrahepatic portal hypertension caused by extrahepatic portal vein thrombosis...
  89. ncbi Experimental investigation of the role of endothelin-1 in idiopathic portal hypertension
    Emi Yamaguchi
    Department of Digestive and General Surgery, School of Medicine, Shimane University, Izumo, Japan
    J Gastroenterol Hepatol 22:1134-40. 2007
    ..have shown that persistent exposure to environmental contaminants including arsenic might induce idiopathic portal hypertension. The aim of this study was to experimentally identify how endothelin-1 is involved in the development of ..
  90. ncbi Non invasive diagnosis of portal hypertension in cirrhotic patients
    F Vizzutti
    Dipartimento di Medicina Interna, Universitá degli, Studi di Firenze Azienda Ospedaliero Universitaria Careggi, Firenze, Italy
    Gastroenterol Clin Biol 32:80-7. 2008
    ..On the other hand, the application of non-invasive methods for monitoring the response to vasoactive treatment for the reduction of portal pressure and the prevention of related complications seems at the moment not realistic...
  91. ncbi Reproducible production of thioacetamide-induced macronodular cirrhosis in the rat with no mortality
    Xiangnong Li
    Liver Sciences Unit, Academic Department of Surgery, St Thomas Hospital, Guy s, King s and St Thomas School of Medicine, London SE1 7EH, UK
    J Hepatol 36:488-93. 2002
    ..The present study developed a modified, reliable, and reproducible technique by which hepatic and systemic responses to thioacetamide during induction of cirrhosis were monitored by weekly weight changes...
  92. ncbi Liver cirrhosis and portal hypertension in cystic fibrosis
    Ori Efrati
    Paediatric Department, The Chaim Sheba Medical Centre, Tel Hashomer, Israel
    Eur J Gastroenterol Hepatol 15:1073-8. 2003
    ..The most deleterious complication of liver disease is portal hypertension, which has an estimated prevalence of up to 8%...
  93. pmc Portal hypertension secondary to myelofibrosis with myeloid metaplasia: a study of 13 cases
    Mohannad Abu-Hilal
    Department of Internal Medicine, Division of Gastroenterology, Mayo Clinic College of Medicine, Rochester, MN 55902, USA
    World J Gastroenterol 15:3128-33. 2009
    To describe the clinical presentation and complications of portal hypertension (PH) secondary to myelofibrosis with myeloid metaplasia (MMM).
  94. ncbi Portal hypertension and portal hypertensive gastropathy in patients with liver cirrhosis: a haemodynamic study
    C Merkel
    Department of Clinical and Experimental Medicine, University of Padua, Via Giustiniani, 2, 35128 Padua, Italy
    Dig Liver Dis 35:269-74. 2003
    The relationships between the levels of portal hypertension and the morphologic alterations of gastric mucosa in patients with liver cirrhosis--generally described as portal hypertensive gastropathy--are poorly defined.
  95. pmc Attenuation of portal hypertension by natural taurine in rats with liver cirrhosis
    Jian Liang
    The Affiliated Ruikang Hospital of Guangxi Traditional Chinese Medical College, Nanning 530011, Guangxi Zhuang Autonomous Region, China
    World J Gastroenterol 15:4529-37. 2009
    To investigate the inhibitory effect of natural taurine (NTau) on portal hypertension (PHT) in rats with experimentally-induced liver cirrhosis (LC).
  96. ncbi Portal hypertension in mansonic schistosomiasis
    S Raia
    Liver Unit, Faculdade de Medicina, Universidade de Sao Paulo, Brazil
    World J Surg 15:176-87. 1991
    ..Among its clinical manifestations, the hepatosplenic form causes portal hypertension which, in turn, brings about severe digestive hemorrhage, the most serious complication of the disease...
  97. ncbi Clinicopathological features of nine cases of non-cirrhotic portal hypertension: current definitions and criteria are inadequate
    C Ibarrola
    Pathology Department, University Hospital Doce de Octubre, Madrid, Spain
    Histopathology 42:251-64. 2003
    The clinicopathological features of nine patients with non-cirrhotic portal hypertension were studied and an attempt was made to apply the descriptive criteria of experts to the morphological alterations of the livers in order to ..
  98. ncbi Aetiology of paediatric portal hypertension - experience of a tertiary care centre in South India
    Ebby G Simon
    Department of Gastrointestinal Sciences, Christian Medical College, Vellore 632004, Tamil Nadu, India
    Trop Doct 39:42-4. 2009
    The aetiological profile of paediatric portal hypertension in our hospital, a tertiary care centre in South India, showed that the commonest causes were extrahepatic portal venous obstruction (EHPVO) and cirrhosis...
  99. ncbi Current state of portosystemic shunt surgery
    Martin Wolff
    Klinik und Poliklinik für Allgemein, Viszeral, Thorax und Gefasschirurgie, Rheinische Friedrich Wilhelms Universitat Bonn, Sigmund Freud Strasse 25, 53105, Bonn, Germany
    Langenbecks Arch Surg 388:141-9. 2003
    ..Surgical shunt procedures continue to be safe, highly effective, and durable procedures to treat variceal bleeding in patients with low operative risk and good liver function...
  100. pmc Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension
    H Reynaert
    Laboratory for Molecular Liver Cell Biology, Free University Brussels VUB, Brussels, Belgium
    Gut 50:571-81. 2002
    ..evidence suggests that stellate cells are involved in the regulation of the liver microcirculation and portal hypertension. Activated hepatic stellate cells have the necessary machinery to contract or relax in response to a number ..
  101. ncbi Expert pediatric opinion on the Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension
    Benjamin Shneider
    Division of Pediatric Hepatology, Department of Pediatrics, Mount Sinai School of Medicine, New York, NY 10029, USA
    Pediatr Transplant 10:893-907. 2006
    b>Portal hypertension leads to a wide variety of complications, which lead to significant morbidity and mortality and are some of the leading reasons for liver transplantation in children with chronic liver disease...

Research Grants64

  1. Pyruvate Dehydrogenase kinase as Therapeutic Target for Hepatic Steatosis, Obesit
    Robert A Harris; Fiscal Year: 2012
    ..a serious condition in which inflammation kills liver cells, ultimately culminating in liver cirrhosis, portal hypertension, and liver failure...
  2. Role of Platelet derived growth factor receptor-a in Liver Patho-biology
    SATDARSHAN SINGH MONGA; Fiscal Year: 2013
    ..Cirrhosis can be further complicated by liver failure, portal hypertension and development of hepatocellular cancer (HCC), making chronic liver disease as the 12th leading cause of ..
  3. Detection of Liver Fibrosis Using IVIM Diffusion and DCE MRI in HCV
    Bachir Taouli; Fiscal Year: 2013
    ..treatment is more effective, and enable a comprehensive evaluation of the liver (to assess for cirrhosis, portal hypertension and hepatocellular cancer)...
  4. UT GASTROENTEROLOGY / HEPATOLOGY RESEARCH TRAINING PROGRAM
    Ezra Burstein; Fiscal Year: 2013
    ..metabolism and gallstone disease;immune responses in the liver and acute liver failure;hepatic fibrosis and portal hypertension;and, viral hepatitis and anti-viral immunity...
  5. SCHISTOSOME EGG INDUCED TH2 RESPONSES
    Edward J Pearce; Fiscal Year: 2013
    ..influences the hepatic macrophage population and determine whether dysregulated thromboxane-A2 production by macrophages underlies the development of severe portal hypertension during chronic schistosomiasis in the absence of antibody.
  6. Biliary Atresia, Cholestatic Liver Diseases, and Cystic Fibrosis: Indiana Univers
    Jean Pappas Molleston; Fiscal Year: 2013
    ..Specific Aim 2: We will conduct studies of portal hypertension in children: We will study the frequency of minimum hepatic encephalopathy (MHE) in children with cirrhosis,..
  7. Colorado Center for Childhood Liver Disease Research and Education
    Ronald J Sokol; Fiscal Year: 2013
    ..deficiencies caused by fat and fat-soluble vitamin malabsorption;and progressive hepatic fibrosis, portal hypertension and eventually chronic liver failure...
  8. Aromatase Inhibitors in Pulmonary Vascular Complications of Liver Disease
    Steven M Kawut; Fiscal Year: 2013
    ..Pulmonary arterial hypertension occurs in 4-8% of patients with portal hypertension (termed portopulmonary hypertension (PPHTN))...
  9. Heme Oxygenase Polymorphisms and Hepatopulmonary Syndrome
    KARI EVAN ROBERTS; Fiscal Year: 2012
    ..The vast majority of patient deaths are due to the complications of portal hypertension including HPS...
  10. Estrogen signaling in portopulmonary hypertension
    Steven M Kawut; Fiscal Year: 2013
    ..is portopulmonary hypertension (PPHTN), defined as pulmonary arterial hypertension (PAH) in the setting of portal hypertension. PPHTN is found in ~6% of patients evaluated for liver transplantation (totaling almost 170,000 Americans ..
  11. Carbamazepine for severe liver disease due to antitrypsin deficiency
    David H Perlmutter; Fiscal Year: 2012
    ..ATZ load by enhancing its intracellular degradation and, as a consequence, reduce hepatic fibrosis and portal hypertension. This hypothesis will be tested through the following specific aims: 1) Determine whether CBZ treatment ..
  12. LDLT: Diagnostic Markers of Liver Regeneration to Predict Outcomes
    Elizabeth A Pomfret; Fiscal Year: 2013
    ..The second aim will investigate the role of portal hypertension in the development of small for size syndrome after LDLT...
  13. MEDIATORS OF PULMONARY VASODILATATION IN LIVER DISEASE
    Michael B Fallon; Fiscal Year: 2013
    ..Pulmonary ETB receptor expression is also increased in prehepatic portal hypertension but hepatic ET-1 production does not rise and HPS does not develop unless ET-1 is infused...
  14. LPS binding to TLR4 regulates hepatic stellate cell activation and fibrosis
    Ekihiro Seki; Fiscal Year: 2013
    ..autoimmune diseases, and non- alcoholic steatohepatitis (NASH), can progress to cirrhosis, liver failure, portal hypertension, and hepatocellular carcinoma...
  15. Arterial Remodeling in Chronic Liver Diseases
    Yasuko Iwakiri; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): In liver cirrhosis, chronic portal hypertension causes hemodynamic abnormalities and leads to thinning of the arterial wall in the splanchnic and systemic circulation...
  16. Mechanisms of Vascular Dysfunction in Cirrhosis
    Sandeep Khurana; Fiscal Year: 2012
    ..b>Portal hypertension is a major cause of morbidity and mortality in advanced liver disease and vascular dysfunction contributes ..
  17. Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension
    Flemming Forsberg; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Common complications of portal hypertension include gastroesophageal varices, ascites, and portasystemic encephalopathy...
  18. Innate Immune Response and Intestinal Inflammation
    Sang Hoon Rhee; Fiscal Year: 2010
    ..Patients with liver fibrosis may progress to cirrhosis with subsequent portal hypertension, hepatic failure and hepatocellular carcinoma...
  19. Function and Mechanism of CUL4 E3 Ligases in Human Diseases
    Yue Xiong; Fiscal Year: 2013
    ..Elevated GRK2 has previously been associated with myocardial infarction, heart failure, portal hypertension, insulin resistance, and Alzheimer's disease...
  20. Impact of infection and inflammation on the toxicity of environmental chemicals
    CHARLES KNUTSON; Fiscal Year: 2013
    ..Arsenic is a ubiquitous environmental contaminant of global water supplies and is associated with hepatic portal hypertension and liver fibrosis in human populations...
  21. Blocking toll-like receptor 4 signaling as therapy in hepatic fibrosis
    BERND G SCHNABL; Fiscal Year: 2013
    ..Patients with liver fibrosis may progress to cirrhosis with subsequent portal hypertension, hepatic failure and hepatocellular carcinoma...
  22. Noninvasive and Accurate Measurement of Portal Hypertension
    Flemming Forsberg; Fiscal Year: 2010
    b>Portal hypertension is defined as an increase in the pressure gradient between the portal vein and hepatic veins or the inferior vena cava (IVC)...
  23. Molecular Mechanisms of Portal Hypertension
    Vijay H Shah; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Portal hypertension and its complications account for much of the morbidity and mortality associated with cirrhosis...
  24. Quantitative Hemodynamics of the Liver with 4D Flow MRI
    Oliver Wieben; Fiscal Year: 2013
    ..non-invasive MRI based method to quantify blood flow in the hepatic vasculature of patients with portal hypertension. Portal hypertension is the most common and lethal complication of end-stage chronic liver disease and ..
  25. The Impact of the MELD Score at the Time of Listing for Liver Transplantation
    Alyson N Fox; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): The prevalence of chronic liver disease, cinliosis and decompensated portal hypertension is on the rise and represents and important public health problem...
  26. Nitric Oxide and the Cellular Pathogenesis of Portal Hypertension
    Don C Rockey; Fiscal Year: 2012
    Increased intrahepatic resistance to blood flow is an important component of many forms of portal hypertension. We and others have recently demonstrated that perisinusoidal stellate cells (Ito cells or lipocytes) exhibit a contractile ..
  27. Mechanism of Liver Fibrosis and TGF-beta Signaling in Congenital Hepatic Fibrosis
    JESSICA WEI YUN WEN; Fiscal Year: 2010
    ..b>Portal hypertension is the major cause of morbidity associated with CHF, causing hypersplenism and esophageal varices...
  28. miRNA Regulation of Aquaporin 1 Modulates Vascular Remodelling during Cirrhosis
    Robert C Huebert; Fiscal Year: 2013
    PROJECT SUMMARY/ABSTRACT Cirrhosis and portal hypertension are the cause of significant morbidity, mortality, and healthcare expenditures...
  29. The Childhood Liver Disease Research and Education Network (ChilDREN)
    SAUL JOSEPH KARPEN; Fiscal Year: 2013
    ..ABCB4 disease, as well as children with BA &CFLD who have evidence of biliary fibrosis/cirrhosis or portal hypertension. Since there are currently no effective medical therapies for cholestasis, proper exploration of the safety ..
  30. Outpatient treatment for portal hypertension
    Elijah M Bolotin; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Portal hypertension (increased pressure in the portal venous system) is one of the main consequences of cirrhosis...
  31. Genetic Risk Factors for Portopulmonary Hypertension
    Steven Kawut; Fiscal Year: 2005
    Patients with portal hypertension are at increased risk of pulmonary hypertension (termed portopulmonary hypertension). Patients with portopulmonary hypertension suffer from increased morbidity and mortality...
  32. DETERMINANTS OF SODIUM RETENTION IN CIRRHOSIS
    WILLIAM RECTOR; Fiscal Year: 1992
    ..We suggest that the first step in ascites formation is development of portal hypertension. This results in portal-systemic shunting of pancreatic glucagon (PG)...
  33. SPLANCHNIC HEMODYNAMICS IN PORTAL HYPERTENSION
    JAMES SITZMANN; Fiscal Year: 1992
    b>Portal hypertension is one of the more serious clinical complications of advanced liver disease...
  34. Effect of Cirrhosis and Shunts on Drug Disposition
    Stephen Hall; Fiscal Year: 2006
    ..1 per 1000 people. The development of portal hypertension is the primary mechanism behind several major complications of cirrhosis such as bleeding from ..
  35. PILOT STUDY OF PIRFENIDONE IN PBC AND PSC
    Keith Lindor; Fiscal Year: 1999
    ..Many patients eventually develop cirrhosis and/or portal hypertension with death caused by hepatic failure unless liver transplantation intervenes...
  36. Molecular Pathogenesis of Cystic Fibrosis Liver Disease
    Martin Carey; Fiscal Year: 2007
    ..Multilobular cirrhosis manifesting clinically with portal hypertension has become the third leading cause of morbidity and premature death in CF, and when pulmonary disease is ..
  37. Liver Derived Microparticles In Cirhossis Pathogenesis
    RAFAL WITEK; Fiscal Year: 2009
    ..b>Portal hypertension and portal-systemic shunting of blood result from changes that occur along hepatic sinusoids during repair/..
  38. GENETICS OF SEVERE HEPATIC FIBROSIS IN SCHISTOSOMIASIS
    RONALD BLANTON; Fiscal Year: 2001
    Severe hepatosplenic disease with portal hypertension, esophageal varices and bleeding is the most serious consequence of infection with schistosoma mansoni...
  39. MODULATORY NETWORK COMPONENETS IN JAPONICA
    GLENN OLDS; Fiscal Year: 1990
    ..Only a relatively small percentage of infected humans (5-10%) develop hepatosplenomegaly, portal hypertension and bleeding esphageal varicies, the leading cause of death in schistosomiasis...
  40. Role of Matrix Metalloproteinase-2 in Liver Fibrosis
    Meena Bansal; Fiscal Year: 2007
    ..Fibrosis with subsequent complications of portal hypertension results in the death of patients awaiting liver transplantation...
  41. Vascular Response to Hemmorhage in Portal Hyprtension
    JAMES SITZMANN; Fiscal Year: 2006
    DESCRIPTION (Provided by Applicant): The protean manifestations of portal hypertension (PHT) lead to the deaths of over 100,000 Americans each year, and disproportionately target minorities and women due to their greater susceptibility ..
  42. STUDY FOR THE TREATMENT OF REFRACTORY ASCITES
    Arun Sanyal; Fiscal Year: 2000
    DESCRIPTION Refractory ascites is a serious complication of cirrhotic portal hypertension and is associated with considerable morbidity, increasing health costs, decreasing quality of life and eventually death or increased risk of death ..
  43. Angiotensin II and NADPH Oxidase in Hepatic Fibrosis
    David Brenner; Fiscal Year: 2009
    ..Liver fibrosis progresses to cirrhosis with subsequent portal hypertension, hepatic failure, and hepatocellular carcinoma, Activated hepatic stellate cells (HSCs) are the major ECM ..
  44. MOLECULAR MODULATION OF MURINE SCHISTOSOMIASIS
    THOMAS KRESINA; Fiscal Year: 1993
    ..laboratory, modulation of fibrosis is characterized by decreased hepatic granuloma size, a reduction in portal hypertension and a switch in the predominate type of collagen which comprises the hepatic fibrosis...
  45. INTESTINE IN CHRONIC PORTAL HYPERTENSION
    JOSEPH BENOIT; Fiscal Year: 2004
    DESCRIPTION: Portal hypertension, a condition that results from cirrhosis or intrahepatic liver disease, is characterized by an elevated portal pressure, portosystemic shunting, an intense intestinal vasodilation and decreased ..
  46. PATHOPHYSIOLOGY OF RECESSIVE POLYCYSTIC KIDNEY DISEASE
    Cathleen Carlin; Fiscal Year: 2004
    ..end-stage renal disease therapy and palliative measures designed to treat the complications of progressive portal hypertension, there is no known therapy for progressive renal cyst formation and enlargement or progressive biliary ..
  47. HEPATOCYTE VOLUME CONTROL AND ALCOHOLIC INJURY
    Robert Wondergem; Fiscal Year: 1993
    ..Liver enlargement in turn leads to portal hypertension, impaired microcirculation, and anoxic degeneration of hepatic function...
  48. TUMOR NECROSIS FACTOR AND PORTAL HYPERTENSION
    Matthew Metz; Fiscal Year: 2003
    DESCRIPTION (provided by the applicant): Portal hypertension (PHT) is a major clinical problem that leads to the death of over 100,000 Americans annually and disproportionately targets minorities and women because of their greater ..
  49. FASEB SUMMER RESEARCH CONFERENCE--SPLANCHNIC CIRCULATION
    CHING CHUNG CHOU; Fiscal Year: 1992
    ..bowel diseases; 6) Hepatic circulation and metabolism; 7) Alcohol effects on the G-I tract and liver; 8) Portal hypertension. The areas of controversy, uncertainty and agreement in these fields will be defined...
  50. STIMULUS/CONTRACTION COUPLING IN HEPATIC STELLATE CELLS
    Hal Yee; Fiscal Year: 2001
    ..indicates that the contractile behavior of activated stellate cells contributes to the development of portal hypertension. Despite extensive study, the processes coupling extracellular stimuli to stellate cell contraction are ..
  51. Cytochrome P450 overexpression and hypertension in SHR
    Scott Carlson; Fiscal Year: 2005
    ..to hypertension in both SHR and an experimental model in which hypertension is concomitantly expressed with portal hypertension and pulmonary dysfunction...
  52. Inhibition of TNF in Patients with Alcoholic Hepatitis
    Vijay Shah; Fiscal Year: 2005
    ..abstract_text> ..
  53. Molecular Mechanisms of Portal Hypertension
    Vijay Shah; Fiscal Year: 2007
    b>Portal hypertension and its complications account for much of the morbidity and mortality associated with cirrhosis. The Long-Term Goal of our lab is to understand the molecular control mechanisms of portal hypertension...
  54. Endothelial Nitric Oxide Synthase & Portal Hypertension
    Vijay Shah; Fiscal Year: 2002
    b>Portal hypertension is a syndrome accounting for significant morbidity and mortality in patients with liver cirrhosis...
  55. REG OF NITRIC OXIDE PRODUCT IN THE HEPATIC CIRCULATION
    Vijay Shah; Fiscal Year: 2002
    ..Understanding the mechanisms that regulate portal pressure is vital as the development of portal hypertension is the single most important factor that determines which patients with cirrhosis will develop ..
  56. Failure of FasL Mediated Pathways in Tumor Angiogenesis
    Vijay Shah; Fiscal Year: 2006
    ..These insights may lead to novel and effective therapeutic strategies that target this pathway to prevent angiogenesis, and thereby prevent colorectal tumor development growth and spread. ..
  57. FACTORS IN THE PREVENTION OF TOXIC LIVER INJURY
    Thomas Boyer; Fiscal Year: 2008
    ..The studies will clarify why expression of certain proteins fall during the acute phase response. ..
  58. ESOPHAGEAL VARICES BY B-ADRENERGIC BLOCKERS
    Roberto Groszmann; Fiscal Year: 2003
    ..It affects men and women equally, and impacts on all races and socio- economical levels. Portal hypertension is the main complication of cirrhosis, regardless of etiology...
  59. NO production and S-nitrosylation in liver vasculature
    Yasuko Iwakiri; Fiscal Year: 2008
    ..NO production by endothelial NO synthase (eNOS) plays a key role in vascular abnormalities observed in portal hypertension in liver cirrhosis...